Evidence map›Paper›PMID 25188449›Full record

ArticleMolecular endocrinology (Baltimore, Md.)2014

Dynamic analysis of GH receptor conformational changes by split luciferase complementation.

Ying Liu, Philip A Berry, Yue Zhang, Jing Jiang, Peter E Lobie, Ramasamy Paulmurugan, John F Langenheim, Wen Y Chen, Kurt R Zinn, Stuart J Frank

Abstract read
In one paragraph

Article in Molecular endocrinology (Baltimore, Md.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Classical and novel GH receptor signaling pathways.Molecular and cellular endocrinology · 2020
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Ying LiuDepartment of Medicine (Y.L., P.A.B., Y.Z., J.J., S.J.F.), Division of Endocrinology, Diabetes, and Metabolism, and Departments of Radiology (K.R.Z.), and Cell, Developmental, and Integrative Biology (S.J.F.), University of Alabama at Birmingham, Birmingham, Alabama 35294; Cancer Science Institute of Singapore and Department of Pharmacology (P.E.L.), National University of Singapore, Singapore 119077; Department of Radiology (R.P.), Stanford University School of Medicine, Palo Alto, California 94304; Department of Biological Sciences (J.F.L., W.Y.C.), Clemson University, Clemson, South Carolina 29634; and Endocrinology Section (S.J.F.), Medical Service, Veterans Affairs Medical Center, Birmingham, Alabama 35233.
Philip A Berry
Yue Zhang
Jing Jiang
Peter E Lobie
Ramasamy Paulmurugan
John F Langenheim
Wen Y Chen
Kurt R Zinn
Stuart J Frank
University of Alabama at Birmingham · USClemson University · USBirmingham VA Medical Center · USNational University Cancer Institute, Singapore · SGStanford University · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Kirk Michael Habegger · 2013 to 2026
$19.5M
Tyrosine Phosphorylation and Growth Hormone SignallingR01DK046395 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FRANK, STUART J · 1997 to 2013
$3.5M
Growth Hormone Receptor Dimerization/Disulfide LinkageR01DK058259 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FRANK, STUART J · 2001 to 2014
$3.4M
Growth Hormone Receptor Dimerization/Disulfide LinkageR56DK058259 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FRANK, STUART J · 2010 to 2010
$220k
Tyrosine Phosphyorylation and Growth Hormone SignalingR56DK046395 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FRANK, STUART J. · 2005 to 2005
$27k
TYROSINE PHOSPHORYLATION AND GROWTH HORMONE SIGNALINGR29DK046395 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FRANK, STUART J. · 1993 to 1996
–
GH Receptor Proteolysis and SheddingI01BX001422 · VA · BIRMINGHAM VA MEDICAL CENTER · PI FRANK, STUART J · 2013 to 2016
–
BLRD VA I01 BX001422NCI NIH HHS P30 CA013148NIDDK NIH HHS DK46395NIDDK NIH HHS DK58259NIDDK NIH HHS P30 DK079626NIDDK NIH HHS R01 DK046395NIDDK NIH HHS R01 DK058259NIDDK NIH HHS R56 DK046395NIDDK NIH HHS R56 DK058259
6 · The paper itself

Abstract

The transmembrane GH receptor (GHR) exists at least in part as a preformed homodimer on the cell surface. Structural and biochemical studies suggest that GH binds GHR in a 1:2 stoichiometry to effect acute GHR conformational changes that trigger the activation of the receptor-associated tyrosine kinase, Janus kinase 2 (JAK2), and downstream signaling. Despite information about GHR-GHR association derived from elegant fluorescence resonance energy transfer/bioluminescence resonance energy transfer studies, an assessment of the dynamics of GH-induced GHR conformational changes has been lacking. To this end, we used a split luciferase complementation assay that allowed detection in living cells of specific ligand-independent GHR-GHR interaction. Furthermore, GH treatment acutely augmented complementation of enzyme activity between GHRs fused, respectively, to N- and C-terminal fragments of firefly luciferase. Analysis of the temporal pattern of GH-induced complementation changes, pharmacological manipulation, genetic alteration of JAK2 levels, and truncation of the GHR intracellular domain (ICD) tail suggested that GH acutely enhances proximity of the GHR homodimer partners independent of the presence of JAK2, phosphorylation of GHR-luciferase chimeras, or an intact ICD. However, subsequent reduction of complementation requires JAK2 kinase activity and the ICD tail. This conclusion is in contrast to existing models of the GHR activation process.

Indexed as

Carrier ProteinsCell LineGrowth HormoneHumansJanus Kinase 2LuciferasesPhosphorylationProtein BindingProtein Structure, TertiarySignal TransductionCarrier ProteinsGrowth HormoneJAK2 protein, humanJanus Kinase 2Luciferasessomatotropin-binding protein

Identifiers

PMID25188449
PMCPMC4213363
OpenAlexW2094112482

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.